A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare the efficacy and safety of simplifying therapy from a
regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a
regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC) without RTV in virologically
suppressed, HIV-1 infected, HLA-B*5701 negative subjects for 48 weeks.